Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, general and administrative expenses

Restructuring and employee severance

Amortization and other acquisition-related costs

Impairments and (gain)/loss on disposal of assets, net

Litigation (recoveries)/charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cardinal Health

Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.On October 4, 2015, Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion.

Cordis

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Cardinal Health reports strong Q3 results, focuses on Pharma growth

Cardinal Health's Q3 results demonstrated strong performance in the Pharma segment, while the Medical segment faced challenges. The company raised its guidance for the year and emphasized the importance of Red Oak Sourcing in maintaining market dynamics. Looking ahead, the company is focused on executing its medical improvement plan and maximizing shareholder value.

Cardinal Health reports stable Q2 growth, eyes Pharma segment

Cardinal Health's Q2 2023 performance showcased stability and growth in the Pharma segment, with a return to profitability in the Medical segment.
The company's strategic focus on executing key priorities and driving shareholder value creation is evident in its financial results.
Challenges such as international freight costs and supply chain headwinds are being addressed, while opportunities in COVID therapies, pricing strategy, and growth investments are being pursued.
Overall, Cardinal Health's revised outlook and strong performance in key segments position it for continued growth and financial success.

Cardinal Health reports robust Q3 earnings, eyes biosimilars for growth

Cardinal Health delivered strong financial performance in Q3 2023, driven by robust growth in the Pharma segment.
While facing challenges in the Medical segment, the company remains focused on mitigating inflation and maximizing shareholder value.
With a positive outlook on future growth opportunities, Cardinal Health aims to address cost pressures and drive profitability.

Cardinal Health achieves record results, raises guidance for fiscal '24

Cardinal Health's strong performance in Q4 and fiscal year 2023, coupled with strategic initiatives and guidance raise, position the company for continued growth and success.
Challenges such as inflation mitigation and cost pressures are being addressed, while opportunities in organic growth and strategic investments pave the way for future profitability.
The company's focus on advancing Pharma, executing the Medical Improvement Plan, and maximizing shareholder value creation underscores its commitment to sustained growth and value creation.

Cardinal Health reports strong Q1 earnings, raises guidance for FY24

Cardinal Health's Q1 2024 earnings call showcased robust performance, with profit growth in both Pharma and Medical segments. The company raised EPS guidance, demonstrated strong cash flow generation, and emphasized customer service and shareholder value creation. Challenges include managing margins, nonoperating items, and commodity price impacts, while opportunities lie in healthcare sector growth, innovation, and market dynamics.

Cardinal Health reports robust Q2 earnings, raises EPS guidance

Cardinal Health's Q2 performance reflects strong revenue growth, improved cash flow, and raised EPS guidance, supported by strategic acquisitions and growth initiatives.
While facing challenges from nonrecurring adjustments and SG&A growth, the company remains focused on core businesses and driving future growth opportunities.
With a positive outlook on market-driven growth, cost management, and strategic priorities, Cardinal Health aims to sustain its momentum and deliver value to shareholders.

Cardinal Health reports robust Q3 earnings, eyes growth opportunities ahead

Cardinal Health's Q3 performance reflects strong financial results and strategic progress across key segments, with raised guidance for fiscal '24 and '25.
The company faces challenges such as managing customer transitions and inflationary impacts but is well-positioned to capitalize on growth opportunities.
By focusing on cost optimization, strategic partnerships, and customer-centric solutions, Cardinal Health aims to drive sustained growth and profitability.
Investments in technology, brand growth, and operational efficiency underscore Cardinal Health's commitment to delivering value to shareholders and customers.

Cardinal Health excels in fiscal '24, raises guidance for '25

Cardinal Health's strong performance in fiscal year '24, highlighted by record financial results and strategic progress, positions the company for continued success.
Despite challenges such as market dynamics and customer transitions, the company's raised guidance for fiscal year '25 underscores confidence in future growth.
By capitalizing on strengths like revenue growth in key segments and making strategic investments, Cardinal Health is poised to navigate challenges and seize opportunities for sustained growth.

Cardinal Health reports strong Q1 performance and raises fiscal guidance

Cardinal Health's Q1 performance showed strength in Pharma and Specialty Solutions despite revenue decrease.
Challenges in GMPD segment and nuclear supply disruptions are being addressed for minimal impact.
Opportunities lie in continued cost reductions, growth normalization, and operational improvements.
Overall, Cardinal Health is well-positioned to navigate challenges and capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cardinal (CAH) reported earnings 30 days ago. What's next for the stock?

Cardinal (CAH) Up 3.1% Since Last Earnings Report: Can It Continue?

AmerisourceBergen

Amneal Pharmaceuticals

Endo International

Johnson & Johnson

McKesson

Mallinckrodt PLC

Teva Pharmaceutical

Shares of the companies embroiled in opioid litigation fell in afternoon trading afterThe Wall Street Journal reported the federal government had opened a criminal investigation into some opioid makers and distributors, citing sources.

Shares of opioid makers and distributors drop on criminal probe

Bristol-Myers

British American Tobacco

Hewlett Packard

Urban Outfitters

PEG-based investing becomes more rewarding when other relevant parameters are considered.

5 Excellent GARP Stocks With Discounted PEG

Cardinal Health (CAH) seems to be a good value pick, as it has decent revenue metrics to back up its earnings, and is seeing solid earnings estimate revisions as well.

Why Cardinal Health (CAH) Could Be a Top Value Stock Pick

AbbVie

Cigna

Agile Therapeutics

Immunomedics

Golden crosses and death crosses are common signals in technical analysis and refer to the relationship between short-term and long-term moving averages.

AbbVie, Cigna and Other Health Care Stocks With Recent Golden Crosses

Cardinal Health, Inc. (CAH) CEO Mike Kaufmann on Fiscal Q1 2020 Results - Earnings Call Transcript

Here's how the big healthcare services and products company outperformed expectations in its fiscal first quarter of 2020.

Cardinal Health Posts a Big Q1 Loss Due to Opioid Litigation but Still Beats Estimates

Cardinal Health (CAH) Q1 results benefit revenue growth and strong segmental performance. However, contraction in gross margin remains a concern.

Cardinal Health (CAH) Q1 Earnings & Revenues Beat Estimates

Cardinal Health CAH, -0.14% reported a $4.92 billion loss, or $16.65 a share, in the fiscal first quarter, due to an agreement in principle it reached in October to pay $5.56 billion to settle pending and potential opioid lawsuits.

Cardinal Health reports $4.9 billion loss due to opioid agreements

Abbott Labs

Penumbra

Varian Medical Systems

DENTSPLY SIRONA

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

Medical Products' Nov 7 Earnings Roster: ABC, CAH & More

Cardinal Health (CAH) Q1 earnings are likely to reflect better-than-expected performance at Pharmaceutical and Medical segments.

What's in the Cards for Cardinal Health (CAH) in Q1 Earnings?

AGNC Investment

Equinor

Energy Transfer LP Unit

FedEx

Iron Mountain

Leggett & Platt

Altria

MPLX

Bank OZK

Packaging Corp of America

Philip Morris

Taubman Centers

Walgreens

I've put good amounts of capital to work, investing heavily into tobacco, oil/energy and some miscellaneous companies as well.

October Portfolio Update - Extensive Buys, More Oil And FX

Cardinal (CAH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cardinal Health (CAH) Expected to Beat Earnings Estimates: Should You Buy?

The first federal trial on the opioid crisis in the United States has been scrapped, after the court agreed to a $260m (£200m) settlement by the country's three largest drug distributors.

US drug giants settle first federal opioids lawsuit for $260m

Four drug companies plan to announce settlements Monday ahead of a massive trial that would accuse them of helping to fuel the nation's crippling opioid crisis, according to a report.

Drug Firms Reportedly Ink Last-Minute Deal Ahead Of Ohio Opioid Trial

CLEVELAND – Four drug companies reached a last-minute legal settlement over their role in the opioid addiction epidemic just as a nine-week trial was scheduled to start in Cleveland, the Wall Street Journal reported Monday.

Four drug companies reach legal settlement for role in opioid addiction epidemic

But drug companies still have thousands of other opioid cases to contend with.

$260 Million Settlement Averts First Federal Opioid Trial

Four drug companies reached a last-minute legal settlement over their role in the opioid addiction epidemic just as a nine-week trial was scheduled to start in Cleveland, the Wall Street Journal reported Monday.

Drug companies reach settlement as opioid trial set to begin

Four drug companies on Monday reached a settlement deal with two Ohio counties on the fight over who is responsible for the opioid epidemic that has ravaged the United States, according to a report in The Wall Street Journal.

Four drug companies reportedly reach a last-minute opioid settlement with two Ohio counties

Shares of McKesson Corp. MCK, +1.16% , Cardinal Health Inc. CAH, +0.64% , AmerisourceBergen Corp.

McKesson, Cardinal Health, Amerisource Bergen and Teva stocks all fall after settling with Ohio counties on opioid suit

The biggest drug distributors, plus Johnson & Johnson and Teva Pharmaceutical, are reportedly on the brink of a $50 billion deal to settle thousands of cases related to the opioid epidemic.

Drug Suppliers Reportedly Near $50 Billion Deal In Opioid Lawsuits

Talks to settle opioid lawsuits sent drug distributor stocks soaring. Trade names at the center of the discussions using these strategies.

Drug Distributor Stocks Rally Amid Opioid Talks

Shares of companies embroiled in the U.S. opioid crisis were trading sharply higher Wednesday following a Tuesday Wall Street Journal report that said three opioid drug distributors are in talks with state and local governments regarding a settlement agreement.

Opioid Drug Companies Rally On Hopes of Broader Settlement

Shares of McKesson Corp. MCK, +6.21% rallied 5.7% in midday trading Wednesday, enough to pace all of its larger-capitalization health care peers, after The Wall Street Journal reported that the drug distributor, and two others, were in talks to pay $18 billion to settle all litigation brought by state and local governments blaming the companies for fueling the opioid crisis.

McKesson, Cardinal Health, AmerisourceBergen stocks surge after WSJ report of $18 billion settlement talks

Archer-Daniels-Midland Company

Caterpillar

Genuine Parts

AT&T

Investors planning for retirement have a significant challenge on their hands, which is to generate enough income to maintain their desired lifestyle, explains Ben Reynolds, a leading specialist on income, a contributor to MoneyShow.com and the editor of Sure Dividend.

News for Cardinal Health Stock (CAH)